Skip to content

    Hikal

    HIKAL
    Healthcare·11 Feb 2026
    Management Summary

    Hikal reported a resilient Q3 FY26 with consolidated revenue of INR494 crores and EBITDA of INR83 crores, marking a positive turning point after navigating regulatory challenges. The Pharmaceutical segment showed strong recovery, though overall pharma growth for FY26 is now expected to be less than double-digit due to FDA-related delays. The Crop Protection segment continued to face margin pressure from overcapacity and pricing, while the company is strategically diversifying into Animal Health and Personal Care, with significant capex investments made in R&D and manufacturing facilities.

    Highlights

    5
    • Consolidated revenue for Q3 FY26 stood at INR494 crores, demonstrating a clear return to operational profitability.

    • EBITDA for Q3 FY26 was INR83 crores, with a margin of 16.8%, indicating sequential improvement in demand visibility and utilization.

    • Pharmaceutical division revenue was INR337 crores with an EBIT margin of 12.3%, signalling a return to normalized trade cycles.

    • Interim dividend of INR0.2 per share, representing 10% of the face value, was approved by the Board.

    • Debt-equity ratio maintained at 0.58 as on December 31, 2025, and finance cost reduced by 17% YoY to INR48 crores.

    Concerns

    3
    • Exceptional item of INR38 crores was provided for new labor code charges, resulting in a reported loss for the quarter.

    • Crop Protection segment revenue stood at INR157 crores with a low EBIT margin of 3%, due to persistent pricing pressures and structural overcapacity.

    • The US FDA audit remediation process, while progressing, has delayed anticipated double-digit growth in the Pharma segment to next year.

    Key financials

    Metrics

    9

    Periods

    2

    Headline

    6
    • Consolidated Revenue
      ₹494 Cr
    • Consolidated EBITDA
      ₹83 Cr
    • Consolidated EBITDA Margin
      16.8%
    • Finance Cost
      ₹48 Cr
      YoY-17%
    • Exceptional Item
      ₹38 Cr

    9M FY26

    3
    • Consolidated Revenue
      ₹1,193 Cr
    • Consolidated EBITDA
      ₹115 Cr
    • Consolidated EBITDA Margin
      9.6%

    Segment breakdown

    • Pharmaceutical₹337 Cr68.2%
    • Crop Protection₹157 Cr31.8%
    Donut· Share of Revenue

    Capital allocation

    3
    high confidence
    CategoryHeadline
    Capex

    ₹150 crores

    cut — conservative approach this year

    Debt

    Debt disclosed

    Dividend

    ₹0.2/share (interim)

    Guidance & targets

    15
    CategoryTargetPriority
    Revenue
    Pharma Business Growth
    some growth, not double-digit
    Medium
    Revenue
    Crop Protection Business Growth
    flattish
    High
    Revenue
    Animal Health Business Size
    INR500 crores plus
    Medium
    Profitability
    Animal Health Gross Margins
    45-50%
    High
    Profitability
    EBITDA for New Businesses
    far in excess of current average
    Medium
    Capex
    Total Capex
    INR150 crores
    High
    Product Launch
    Milvexian KSM Launch
    next year
    High
    Product Launch
    NCE Launch Velocity
    2 to 3 new products annually
    High
    Product Launch
    Commercial Launch of Key Starting Materials (Phase III)
    scheduled
    High
    Production
    Peak Output for 2 Custom Products
    achieve peak output
    High
    Utilization
    Animal Health Facility Utilization
    increase
    Medium
    Plant Repurposing
    Agri Plant Repurposing (Phase I)
    implemented
    High
    Plant Repurposing
    Agri Plant Repurposing (Phase II)
    implemented
    High
    Debt
    Overall Debt Reduction
    start seeing a reduction
    High
    Performance
    Q4 FY26 Performance
    better than Q3
    High

    US FDA Remediation Plan Outcome

    within next 2 weeks (from Feb 11, 2026)
    CurrentRemediation plan submitted, last update Feb 9, 2026
    TargetHearing back from FDA on satisfaction with progress, potential reinspection

    Why it matters

    Resolution of the FDA warning letter is crucial for the Pharmaceutical segment's full recovery and growth trajectory.

    Now after completion of the warning letter, which will be of 6 months, which will just get over in the next 2 weeks, we should be hearing back from them, and then we'll get to know whether they are satisfied with the progress of our remediation plan.

    How to verify

    risks_and_concerns[risk='Regulatory scrutiny and US FDA audit impact']

    Risks & concerns

    6
    RiskSeverity

    Global macroeconomic effects

    Operating environment remains dynamic due to global macroeconomic effects.Management acknowledged

    medium

    Structural overcapacity and pricing pressure in Global Crop Protection

    Particularly from China, continues to exhibit pressure on pricing and availability of products, leading to low EBIT margin of 3% in Q3 FY26.Management acknowledged

    high

    Evolving trade policies

    Introducing a degree of volatility into procurement decisions and supply chain dynamics.Management acknowledged

    medium

    Regulatory scrutiny and US FDA audit impact

    Temporarily impacted Pharmaceutical segment performance and delayed double-digit growth expectations for FY26.Management acknowledged

    high

    Gestation period and high capex for ADCs

    ADCs require OEB 5 certification, 2-3 years gestation, and 3x normal plant capex, which is a complex and capital-intensive area.Analyst acknowledged

    medium

    Patent expiry and competition in Animal Health products

    Products like Afoxolaner and Fluralaner face significant competition and price erosion post-patent expiry, shifting focus to CDMO.Analyst acknowledged

    medium

    Q&A highlights

    8

    “So we have given our remediation plan to U.S. FDA. We don't give them a monthly update, but we are giving an update once in 6 weeks. The last 2 updates were given on December 16 and as recent as this Monday, which is February 9. Now after completion of the warning letter, which will be of 6 months, which will just get over in the next 2 weeks, we should be hearing back from them, and then we'll get to know whether they are satisfied with the progress of our remediation plan.”

    Provides a clear timeline and status update on the critical FDA remediation process, indicating an expected response within two weeks.

    asked by Henil

    3 min read6 chapters

    Detailed Narrative

    01

    Q3 FY26 Performance Overview and Recovery

    Hikal reported consolidated revenue of INR494 crores and EBITDA of INR83 crores for Q3 FY26, translating to an EBITDA margin of 16.8%. This marks a clear return to operational profitability, supported by improved demand visibility and utilization. For the nine months ended December 31, 2025, consolidated revenue stood at INR1,193 crores with an EBITDA of INR115 crores (9.6% margin). The company anticipates a strong recovery in H2 FY26, with Q4 expected to outperform Q3.

    02

    Pharmaceutical Segment Performance and Regulatory Progress

    The Pharmaceutical division delivered INR337 crores in revenue for Q3 FY26, achieving an EBIT margin of 12.3%. This performance signals a return to normalized trade cycles after previous headwinds. Remedial actions concerning the US FDA audit are progressing well, with the remediation plan submitted and an update provided on February 9. The company expects to hear back from the FDA within two weeks, and double-digit volume growth in pharma is anticipated to return next year, delayed by approximately one quarter due to the FDA impact.

    03

    Crop Protection Segment Challenges and Diversification

    The Crop Protection segment recorded revenues of INR157 crores with a low EBIT margin of 3% in Q3 FY26. This segment continues to face persistent pricing pressures and structural overcapacity, particularly from China. In response, Hikal is accelerating its portfolio diversification strategy, focusing on specialty chemicals, especially the Personal Care segment. The company expects meaningful revenue from this new segment to commence in the next fiscal year, with 2 products already commercialized in Q3.

    04

    Strategic Investments and R&D Pipeline

    Hikal has made strategic investments over the last 12-15 months, including a state-of-the-art high-potency laboratory and R&D centre in Pune (INR10-11 crores for Phase I) and a new pilot plant in Panoli. These facilities enhance its CDMO capabilities in high-technology segments. The R&D pipeline is robust, with 8-9 molecules in advanced stages, and the company aims for a launch velocity of 2-3 new products annually. Key starting materials for global innovators are in Phase III clinical trials, with commercial launch scheduled for FY28.

    05

    Capital Allocation and Debt Management

    The Board approved an interim dividend of INR0.2 per share (10% of face value). Capital expenditure for the first nine months of FY26 stood at INR100 crores, focused on debottlenecking and capacity expansion. The full-year FY26 capex guidance has been revised downwards from INR200 crores to INR150 crores. Finance costs reduced by 17% YoY to INR48 crores, and the debt-equity ratio was maintained at 0.58 as of December 31, 2025. The company also reduced working capital by INR50 crores in 9M FY26 compared to March 2025, and anticipates overall debt reduction from FY29 onwards.

    06

    Animal Health Business Growth and Outlook

    The Animal Health business continues to see sustained momentum, driven by outsourcing trends and a steady pipeline of new development projects. Hikal has a master plan to build this into an INR500 crores plus business within the next 4-5 years, with gross margins expected to be in the 45-50% range. While volumes are not yet tremendously large, they are growing, and utilization of Animal Health facilities is expected to increase in FY27 as global approvals come through for customer products.

    This is an AI-generated summary of a publicly available earnings call transcript. It is for informational purposes only and does not constitute investment advice, a recommendation, or an endorsement. inve.money is not a SEBI-registered investment advisor. Please consult a qualified financial advisor before making any investment decisions.